IGMPI Approvals & Accreditation : Approved by Quality Council of India (QCI) & Accredited Vocational Institution of Ministry of HRD, Government of India, Approved Training Institute of Food Safety and Standards Authority of India (FSSAI), Recognized by Department of Industrial Policy & Promotion, Ministry of Commerce & Industry, Government of India, An ISO 9001:2015 Certified Organisation registered under The Societies Registration Act,1860 Government of India Empanelled under Ministry of Horticulture and Food Processing, Government of Uttar Pradesh, Affiliated with Life Sciences and Food Industry Sector Skills Council (SSC)
Trusted by organizations & training participants in over 30 countries. Training | Certification | Education | Research

Phase 3 Revatio (Sildenafil Citrate) trial results announced by Pfizer

28th June 2019

When the pulmonary arteries become narrower or obstructed, then the condition is known as Pulmonary Hypertension. Due to this condition, right ventricle of the heart is in lot of pressure to work hardly to pump blood leading to weakening and organ enlargement. When it is present in newborn babies, it is called as Persistent Pulmonary Hypertension of Newborn or neonatal pulmonary hypertension.

As per the Pfizer, Inc. announcement, a phase 3 trial was conducted to study the safety and efficacy of intravenous Sildenafil. When added to Nitric Oxide; which is inhaled for the treatment of newborns with Persistent Pulmonary Hypertension, Sildenafil did not attain its primary efficacy endpoint.

This study had two consecutive parts. Part A consisted of randomized, placebo-controlled, double-blind interventional phase to examine safety and efficacy. Part B is the non-interventional phase with a follow-up at 12 and 24 months after the end of study treatment for evaluating developmental progress. The result obtained is solely based on the observation from Part A of the study; Part B is ongoing.

The profile of safety and adverse events observed in this study was comparable to the known safety profile of Revatio in earlier studies in pediatric and adult patients with pulmonary arterial hypertension taking Revatio.

For further enquiries, write to or call us on:
info@igmpiindia.org/ +91 8587838177, +91 8130924488, 0120-2427175, 0120-4375280

Pharmaceuticals | Food | Clinical Research | Healthcare | Medical Coding | Medical Device | Nanotechnology | IPR

Clinical Research Newsletter

Featured Article

GMP: A continous process

Mr Vinod Arora, Principal Advisor, IGMPI

IGMPI Placement Blog

Placement Testimonials

Placement testimonials: Our alumni are working with Fortune 500 and global Pharmaceutical, Food and healthcare giants like